Arap et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model”, Science, vol. 279, pp. 377-380, Jan. 16, 1998.* |
Anderson, “The Use of Esters of N-Hydroxysuccinimide in Peptide Synthesis,” J. Am. Chem. Soc. 86:1839 (1964). |
Arap, “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in Mouse mOdel,” Science 279:377-80 (1998). |
Bleicher et al., “Biochemical Mechanism of Cross-resistance to Paclitaxel in a Mitomycin c-Resistant Human Bladder Cancer Cell Line,” Cancer Lett 150(2):129-35 (2000). |
Choudhuri et al. “Reversal of Resistance Against Doxorubicin by a Newly Developed Compound, Oxalyl Bis(N-phenyl)hydroxamic Acid in Vitro,” Anti-Cancer Drugs 9:825-32 (1998). |
Dun et al., “Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype,” Clin. Cancer Res. 5(11):3445-53 (1993). |
Elias, Anthony D., “Advances in the diagnosis and management of sarcomas,” Current Opinion in Oncology 4:681-8 (1992). |
Gonzalez-Garay, “A β-Tubulin Leucine Cluster Involved in Microtubule Assembly and Paclitaxel Resistance,” J. Biol. Chem., 274:23875-882 (1999). |
Harris et al., “Mechanisms of Multidrug Resistance in Cancer Treatment,” Acta Oncological 31:205-13 (1992). |
Janaky et al., “Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups,” Proc Batl. Acad. Sci. USA 89:972-76 (1992). |
Janaky et al., “Short-Chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties,” Proc. Natl. Acad. Sci. USA 89:10203-7 (1992). |
Magri et al., “Modified Taxols, 4. Synthesis and Biological Activity of Taxols Modified in the Side Chain,” Journal of Natural Products 51(2):298-306 (1988). |
Monzo et al., “Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations,” J. Clin. Oncol. 17(6):1786-93 (1999). |
Nagy et al., “Cytotoxic Analogs of Luteinizing Hormone-Releasing Hormone Containing Doxorubicin,” PNAS 93:7269-73 (1996). |
O'Brien et al., “Glutathione peptidomimietic drug modulator of multidrug resistance-associated protein,” J Pharmacol Exp Ther 291(3):1348-55 (1999). |
Priebe et al., “Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity,” Anti-Cancer Drugs 4:37-48 (1993). |
Rahman, “Modulation of Multidrug Resistance in Cancer Cells by Liposome Encapsulated Doxorubicin,” J. Liposome Res. 4:575-604 (1994). |
Reinecke et al., “Growth Inhibitory Effects of Paclitaxel on Human Epitheloid Sarcoma in Vitro: Heterogeneity of Response and the Multidrug Resistance Phenotype,” Cancer 88(7):1614-22 (2000). |
Sackett, Fojo T., “Taxanes and other microtubule stabilizing agents,” Cancer Chemother Biol Response Modif 18:59-80 (1999). |
Safavy, “Paclitaxel Derivatives for Targeted Therapy of Cancer: Toward the Development of Smart Taxanes,” J. Med. Chem. 42:4919-24 (1999). |
Schuurhuis et al., “Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumor cells,” BJC 898-908 (1993). |
Stan et al., “Antineoplastic Efficacy of Doxorubicin Enzymatically Assembled on Galactose Residues of a Monoclonal Antibody Specific for the Carcinoembryonic Antigen,” Cancer Res. 59:115-21 (1999). |
Tuszynski et al., “Localization of Thrombospondin and Its Cysteine-Serine-Valine-Threonine-Cysteine-Glycine-Specific Receptor in Human Breast Carcinoma,” Laboratory Investigation 70(2):228-32 (1994). |
Yang et al., “Reversal of Doxorubin Resistance by Doxorubicin-gallium-transferrin Conjugate in Human Breat Cancer Cell Lines,” Proc. Am. Assn. Cancer Res. 40:4377 (1999). |
Zunino et al., “Interaction of Daunomycin and its Derivatives with DNA,” Biochim. Biophys. Acta 227:489-98 (1972). |
Asakura, et al., “Drug Conjugate of Doxorubicin with Glutathione is a Potent Reverser of Multidrug Resistance in Rat Hepatoma Cells,” Anti-Cancer Drugs, 8(2): 199-203 (1997). |
Asakura, et al., “Glutathione-Doxorubicin Conjugate Expresses Potent Cytotoxicity by Suppression of Glutathione S-Transferase Activity: Comparison Between Doxorubicin-Sensitive and -Resistant Rat Hepatoma Cells,” British Journal of Cancer, 76(10): 1333-1337 (1997). |
Barinaga, “Peptide Guided Cancer Drugs Show Promise in Mice,” Science, 279:323-324 (1998). |
Mazzoni, et al., “Comparative Distribution of Free Doxorubicin and Poly-L-Aspartic Acid Linked Doxorubicin in MS-2 Sarcoma Bearing Mice,” Cancer Drug Delivery, 3(3): 163-172 (1986). |
Nagy, et al., “Cytotoxic Analogs of Luteinizing Hormone Releasing Hormone Containing Doxorubicin or 2-Pyrrolinodoxorubicin, a Derivative 500-1000 Times More Potent,” Proc. Natl. Acad. Sc., 93(14): 7269-7273 (1996). |
Pratesi, et al., “Poly-L-Aspartic Acid as a Carrier for Doxorubicin: A Comparative In Vivo Study of Free and Polymer-Bound Drug,” British Journal of Cancer, 52: 841-848 (1985). |
Safavy, et al., “Paclitaxel Derivatives for Targeted Therapy of Cancer Toward the Development of Smart Taxanes,” J. Med. Chem., 42(23): 4919-4924 (1999). |
Zunino, et al., “Comparison of Antitumor Effects of Daunorubicin Covalently Linked to Poly-L-Amino Acid Carriers,” Eur J. Cancer Clin Oncol, 20(3): 421-425 (1984). |